Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
Go back to Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 62.84 -0.76 (1.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $63.60 | 52 Week High | $77.12 | |||
| Open | $64.08 | 52 Week Low | $49.03 | |||
| Day High | $64.35 | P/E | 40.81 | |||
| Day Low | $62.52 | EPS | $1.54 | |||
| Volume | 12,212,778 | |||||
